Janux Therapeutics (JANX) Retained Earnings: 2020-2025
Historic Retained Earnings for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to -$319.4 million.
- Janux Therapeutics' Retained Earnings fell 46.84% to -$319.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.4 million, marking a year-over-year decrease of 46.84%. This contributed to the annual value of -$237.8 million for FY2024, which is 40.88% down from last year.
- Latest data reveals that Janux Therapeutics reported Retained Earnings of -$319.4 million as of Q3 2025, which was down 8.24% from -$295.1 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Retained Earnings registered a high of -$23.2 million during Q2 2021, and its lowest value of -$319.4 million during Q3 2025.
- For the 3-year period, Janux Therapeutics' Retained Earnings averaged around -$209.4 million, with its median value being -$189.5 million (2024).
- Data for Janux Therapeutics' Retained Earnings shows a maximum YoY crashed of 234.53% (in 2022) over the last 5 years.
- Over the past 5 years, Janux Therapeutics' Retained Earnings (Quarterly) stood at -$47.4 million in 2021, then crashed by 133.00% to -$110.5 million in 2022, then crashed by 52.77% to -$168.8 million in 2023, then tumbled by 40.88% to -$237.8 million in 2024, then crashed by 46.84% to -$319.4 million in 2025.
- Its Retained Earnings was -$319.4 million in Q3 2025, compared to -$295.1 million in Q2 2025 and -$261.3 million in Q1 2025.